Boyapati A, et al. High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response. ACR 2018, abstract L08.
Vroege progressie voorspelt overleving van patiënten met sclerodermie en longfibrose
apr 2019 | ILD, Sclerodermie